- Home
- PMAX vs RNXT Comparison
PMAX vs RNXT Comparison
Compare PMAX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- RNXT
- Stock Information
- Founded
- PMAX 2019
- RNXT 2012
- Country
- PMAX Hong Kong
- RNXT United States
- Employees
- PMAX N/A
- RNXT N/A
- Industry
- PMAX
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- RNXT Health Care
- Exchange
- PMAX Nasdaq
- RNXT Nasdaq
- Market Cap
- PMAX 32.0M
- RNXT 33.8M
- IPO Year
- PMAX 2024
- RNXT 2021
- Fundamental
- Price
- PMAX $0.64
- RNXT $1.50
- Analyst Decision
- PMAX
- RNXT Strong Buy
- Analyst Count
- PMAX 0
- RNXT 2
- Target Price
- PMAX N/A
- RNXT $6.50
- AVG Volume (30 Days)
- PMAX 2.2M
- RNXT 101.2K
- Earning Date
- PMAX 02-11-2025
- RNXT 11-13-2024
- Dividend Yield
- PMAX N/A
- RNXT N/A
- EPS Growth
- PMAX N/A
- RNXT N/A
- EPS
- PMAX 0.04
- RNXT N/A
- Revenue
- PMAX $5,970,263.00
- RNXT N/A
- Revenue This Year
- PMAX N/A
- RNXT N/A
- Revenue Next Year
- PMAX N/A
- RNXT N/A
- P/E Ratio
- PMAX $14.90
- RNXT N/A
- Revenue Growth
- PMAX 30.05
- RNXT N/A
- 52 Week Low
- PMAX $0.62
- RNXT $0.77
- 52 Week High
- PMAX $4.70
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- RNXT 64.78
- Support Level
- PMAX N/A
- RNXT $1.26
- Resistance Level
- PMAX N/A
- RNXT $1.60
- Average True Range (ATR)
- PMAX 0.00
- RNXT 0.12
- MACD
- PMAX 0.00
- RNXT 0.01
- Stochastic Oscillator
- PMAX 0.00
- RNXT 72.22
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.